Marks & Clerk expertise cited in American Biotech publication, Endpoints News

We are delighted to see M&C Managing Associate Nick Fischer cited in Endpoints News this week discussing the recent announcement from the MHRA about the "new international recognition framework" to replace the existing European Commission Decision Reliance Procedure.  

Full details of the article can be found below and a link to Nick's full commentary can be found here. 

An in­tel­lec­tu­al prop­er­ty law firm says that re­cent guid­ance from the UK’s Med­i­cines and Health­care prod­ucts Reg­u­la­to­ry Agency hints at the pos­si­bil­i­ty of the agency al­low­ing ap­provals from oth­er reg­u­la­tors, in­clud­ing pos­si­bly the US FDA, to play a role in UK reg­u­la­to­ry process­es. Marks & Clerk, based out of Lon­don, wrote in a blog post that guid­ance from the UK’s reg­u­la­to­ry agency from late Jan­u­ary is pro­vid­ing more con­text in­to po­ten­tial in­ter­na­tion­al col­lab­o­ra­tion with oth­er reg­u­la­tors. How that would come about is af­ter the UK’s “Re­liance Pro­ce­dure” — a way to en­sure pa­tients in Great Britain post-Brex­it could still ac­cess new med­i­cines — ex­pires.

endpts.com/...